The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 675-681

  Guthrie, K A ^a   Yong, M ^a   Frieze, D ^b,c   Corey, L ^a,c   Fredricks, D N ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Ceftazidime; Hematopoietic cell transplant; Levofloxacin; Neutropenia; Prophylaxis

Indexed keywords

BACTERIAL ANTIGEN; CEFTAZIDIME; LEVOFLOXACIN;

ADULT; ADVERSE OUTCOME; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIGEN DETECTION; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATION; BACTERIURIA; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG COST; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; STREPTOCOCCUS VIRIDANS INFECTION; TREND STUDY; WOUND INFECTION;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CEFTAZIDIME; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 77950607013     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.216     Document Type: Article

References (16)

1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751. (Pubitemid 34194843)
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
4. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
5. Petersen F, Thornquist M, Buckner C, Counts G, Nelson N, Meyers J et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16: 199-208.
6. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis (Review). J Antimicrob Chemother 2007; 59: 5-22. (Pubitemid 46017895)
7. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients [erratum appears in Ann Intern Med. 2006 May 2;144(9):704]. Ann Intern Med 2005; 142: 979-995. (Pubitemid 40840313)
8. von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006; 58: 891-894. (Pubitemid 44390974)
9. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987. (Pubitemid 41262332)
10. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998. (Pubitemid 41262333)
11. Gafter-Gvili A, Fraser A, Paul M, van de WM, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (Review). Cochrane Database of Systematic Review, vol 4, 2005, Article no. CD004386.
12. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions (Review). Cancer 2006; 107: 1743-1751. (Pubitemid 44582942)
13. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353: 1052-1054.
14. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260. (Pubitemid 41532667)
15. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality [erratum appears in N Engl J Med 2006; 354: 2200]. N Engl J Med 2005; 353: 2442-2449. (Pubitemid 41770165)
16. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469-1474. (Pubitemid 34553706)